Page 135 - Predicting survival in patients with spinal bone metastasesL
P. 135

                                2015
Bollen L, Wibmer C, Wang M, Van der Linden YM, Leithner A, Bünger CE, Jensen AB, Fiocco M, Bratschitsch G, Pondaag W, Bovée JVMG, Dijkstra PDS. Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases. Clin. Exp. Metastasis. 2015; 32(1):1-5.
2016
Bollen L, Wibmer C, Van der Linden YM, Pondaag W, Fiocco M, Peul WC, Marijnen CAM, Nelissen RGHH, Leithner A, Dijkstra PDS. Predictive value of six prognostic scoring systems for spinal bone metastases – An analysis based on 1379 patients. Spine 2016; 41(3):155-162.
2017
Willeumier JJ, Van der Hoeven N, Bollen L, Willems LNA, Fiocco M, Van der Linden YM, Dijkstra PDS.
Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer. Bone Joint J. 2017;99(4):516-521.
Bollen L, Groenen K, Pondaag W, Van Rijswijk CSP, Fiocco M, Van der Linden YM, Dijkstra PDS. Clinical evaluation of the Spinal Instability Neoplastic Score in patients treated with radiotherapy for symptomatic spinal bone metastases. Spine. 2017;42(16):956-962.
LIST OF PUBLICATIONS
 133

























































































   133   134   135   136   137